SEC Form SC 13G/A filed

2/8/21 10:17:35 AM ET

Medical/Dental Instruments

Health Care

Get the next $BDX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 2 BECTON DICKINSON & CO COMMON STOCK Cusip #075887109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #075887109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 569,995 Item 6: 0 Item 7: 4,969,299 Item 8: 0 Item 9: 4,969,299 Item 11: 1.707% Item 12: HC Cusip #075887109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,969,299 Item 8: 0 Item 9: 4,969,299 Item 11: 1.707% Item 12: IN Item 1(a). Name of Issuer: BECTON DICKINSON & CO Item 1(b). Address of Issuer's Principal Executive Offices: One Becton Drive Franklin Lakes, NJ 07417-1880 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 075887109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 4,969,299 (b) Percent of Class: 1.707% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 569,995 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,969,299 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of BECTON DICKINSON & CO. No one other person's interest in the COMMON STOCK of BECTON DICKINSON & CO is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 5, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 5, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of BECTON DICKINSON & CO at December 31, 2020. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $BDX alert in real time by email

Recent Analyst Ratings for

$BDX

Date	Price Target	Rating	Analyst
5/22/2025	$185.00	Buy → Neutral	Citigroup
5/2/2025	$185.00	Overweight → Neutral	Piper Sandler
5/2/2025	$192.00	Buy → Neutral	Goldman
5/2/2025		Outperform → Mkt Perform	Raymond James
5/1/2025		Overweight → Equal Weight	Wells Fargo
5/1/2025	$190.00	Buy → Neutral	BofA Securities
5/1/2025		Outperform → Mkt Perform	William Blair
10/1/2024	$255.00 → $275.00	Neutral → Buy	Citigroup

More analyst ratings

SEC Form SC 13G/A filed

Chat with this insight

Recent Analyst Ratings for $BDX

$BDX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP and Chief ISC Officer Shan David sold $199,608 worth of shares (1,166 units at $171.19), decreasing direct ownership by 20% to 4,575 units (SEC Form 4)

SEC Form 4 filed by Director Jones Christopher Ian Montague

SEC Form 4 filed by Director Byington Carrie L

$BDX SEC Filings

Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form SD filed by Becton Dickinson and Company

Becton Dickinson and Company filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

$BDX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Becton Dickinson downgraded by Citigroup with a new price target

Becton Dickinson downgraded by Piper Sandler with a new price target

Becton Dickinson downgraded by Goldman with a new price target

$BDX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

$BDX Press Releases

Fastest customizable press release news feed in the world

BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease

BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'

$BDX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

$BDX Financials

Live finance-specific insights

BD Reports Second Quarter Fiscal 2025 Financial Results

BD Board Declares Dividend

BD Reports First Quarter Fiscal 2025 Financial Results

$BDX Leadership Updates

Live Leadership Updates

BD Names Gregory J. Hayes to Board of Directors

Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Revelyst Announces Chief Supply Chain Officer

$BDX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

Recent Analyst Ratings for
$BDX

$BDX
Insider Trading

$BDX
SEC Filings

$BDX
Analyst Ratings

$BDX
FDA approvals

$BDX
Press Releases

$BDX
Insider Purchases

$BDX
Financials

$BDX
Leadership Updates

$BDX
Large Ownership Changes